OTC Manufacturers Less Likely To Face Inspection Under cGMP Pilot
This article was originally published in The Tan Sheet
Executive Summary
Manufacturing facilities that produce OTC drugs exclusively may not be inspected as often as plants that make prescription drugs under FDA's risk-based prioritization plan for inspections